263 - Take It in the Arm: New and Evolving Vaccines and Strategies

Saturday, October 19, 2024

3:15 PM – 4:30 PM US PT

Location: Concourse 152

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Lisa Jackson, MD, MPH (she/her/hers)

Senior Investigator
Kaiser Permanente Washington Health Research Institute
Seattle, WA, United States
C. Mary Healy, MD, FIDSA (she/her/hers)

Associate Professor of Pediatrics, Infectious Diseases
Baylor College of Medicine
Houston, TX, United States

Faculty(s)

Stefan Gravenstein, MD, MPH

Professor of Medicine and Health Services Policy and Practice, Director of Geriatrics and Palliative Medicine
Medicine/Geriatrics
Brown University
Providence, RI, United States
Afzal Siddiqui, PhD (he/him/his)

Professor & Chair
Texas Tech University Health Sciences Center
Lubbock, TX, United States
Joshua Wong, MD (he/him/his)

Medical Officer
CDC Dengue Branch

Disclosure(s):

Lisa Jackson, MD, MPH: No financial relationships to disclose

C. Mary Healy, MD, FIDSA: Dexcom Inc: Stocks/Bonds (Public Company); Hillevax, Inc: Member of Advisory board; Intuitive Surgical Inc: Stocks/Bonds (Public Company); Quidel Corporation: Stocks/Bonds (Public Company); Vapotherm: Stocks/Bonds (Public Company)

Stefan Gravenstein, MD, MPH: AstraZenca: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing); Centers for Disease Control and Prevention (CDC): Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Department of Veterans Affairs: Grant/Research Support (Ongoing); Genentech: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing); GSK: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Icosavax: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing); Janssen Vaccines & Prevention B.V.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing); Johnson & Johnson/Janssen Pharmaceuticals: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Moderna, Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing); NIH and/or NIAID: Grant/Research Support (Ongoing); Pfizer Pharmaceuticals: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing); Sanofis Pasteur: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing)

Afzal A. Siddiqui, PhD: No financial relationships to disclose

Joshua Wong, MD: No financial relationships to disclose

Learning Objectives:

At the conclusion of this session, participants will be able to:

identify new vaccines and strategies to prevent expec, schistosomiasis and dengue infections;
describe the importance of preclinical work for development of novel vaccines;
determine strategies for use of dengue vaccines to prevent infection in endemic pediatric populations.

Presentations:

3:15 PM – 3:40 PM US PT

The Burden of Extraintestinal Pathogenic E coli (ExPEC) and Progress in Clinical Trials
Speaker: Stefan Gravenstein, MD, MPH – Brown University
3:40 PM – 4:05 PM US PT

A new vaccine for an ancient plague: development of a schistosomiasis vaccine
Speaker: Afzal A. Siddiqui, PhD (he/him/his) – Texas Tech University Health Sciences Center
4:05 PM – 4:30 PM US PT

Update on Dengue Vaccines
Speaker: Joshua Wong, MD (he/him/his) – CDC Dengue Branch